AHS Recommends CGRP Therapies as First-Line Migraine Prevention

The American Headache Society (AHS) has updated its position on calcitonin gene-related peptide (CGRP)-targeting therapies, recommending them as first-line treatments for migraine prevention due to their proven efficacy, safety, and tolerability. This marks a significant shift from previous therapies, which were developed for other conditions. At the upcoming American Academy of Neurology Annual Meeting, expert Andrew Charles will discuss the growing support for CGRP antagonists in treating migraines. Meanwhile, Teva Pharmaceuticals is seeking FDA approval for AJOVY, a CGRP antagonist aimed at preventing episodic migraines in children, highlighting the urgent need for effective pediatric migraine treatments. Studies indicate that regular orgasms may also alleviate migraine symptoms by releasing 'happy hormones,' providing a non-pharmaceutical option for some sufferers. As CGRP therapies gain traction, pharmacists are playing a crucial role in patient education and management of these new treatments.